Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | GSK3A | P49840 | 13/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710978 | 1.00 | GSK3B (1.00) | GSK3BGSK3AMAPT | |
| SCHEMBL16710968 | 0.93 | MAPT (1.00) | GSK3BGSK3AMAPT | |
| SCHEMBL19558485 | 0.93 | MAPT (1.00) | GSK3BGSK3AMAPT | |
| SCHEMBL19558469 | 0.93 | MAPT (1.00) | GSK3BGSK3AMAPT | |
| SCHEMBL16702908 | 0.92 | GSK3B (0.88) | GSK3BGSK3AMAPT | |
| SCHEMBL16704170 | 0.91 | GSK3B (1.00) | GSK3BGSK3AMAPT | |
| SCHEMBL16710967 | 0.91 | GSK3B (1.00) | GSK3BGSK3AMAPT | |
| SCHEMBL19558456 | 0.91 | GSK3B (1.00) | GSK3BGSK3AMAPT | |
| SCHEMBL18107511 | 0.91 | GSK3B (0.83) | GSK3BGSK3AMAPT | |
| SCHEMBL16703032 | 0.90 | GSK3B (0.81) | GSK3BGSK3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269129-A1 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | THE BROAD INSTITUTE, INC. | 2024-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269129-A1 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | GSK3B, GSK3A, CTNNB1 | GSK3B 1/4885GSK3A 2/4885MAPT 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.